Navigation Links
AbbVie's Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
Date:5/6/2013

-formulated tablets of ABT-450/r and ABT-267 are being used in the Phase 3 trials.

About the Hepatitis C Virus  Across the world, about 160 million people are chronically infected with hepatitis C.(2) Hepatitis C is an inflammation of the liver caused by an infection with the hepatitis C virus (HCV).(3)  HCV is transmitted when an infected person's blood enters the bloodstream of another person.(4)

For the hepatitis C virus, there are six major HCV genotypes (GT1-6).(5) Presently, there is no vaccine for the hepatitis C virus (HCV) infection.(5) Decision to treat is dependent on a number of factors such as the amount of liver damage present, other conditions the patient may have, amount of virus in the body, and viral genotype.(5) If treatment is needed, a hepatitis C infection is typically treated with a combination of antivirals.(5)

About AbbVie's HCV Development ProgramsAbbVie's HCV portfolio includes investigational medicines with three different mechanisms of action, including protease (ABT-450/r), polymerase (ABT-333) and NS5A (ABT-267) inhibitors, currently being studied in clinical trials. ABT-450 is being developed with low dose ritonavir which enhances the pharmacokinetic properties of ABT-450. The use of ritonavir 100mg with ABT-450 for the treatment of HCV is investigational.

ABT-450 was discovered during the course of a collaboration between AbbVie and Enanta Pharmaceuticals for HCV protease inhibitors and regimens that include protease inhibitors. ABT-450 is being developed by AbbVie for use in combination with AbbVie's other investigational medicines for the treatment of HCV. AbbVie is well-positioned to explore combinations and co-formulations of these medicines.

Ritonavir Use in the Treatment of HIVRitonavir is in a class of medicines called the HIV protease inhibitors. Ritonavir is used in combination with other anti-
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
2. Bayers Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
3. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
4. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
5. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
6. Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2
7. Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
8. Scioderms Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA
9. BHR Pharma Investigational Traumatic Brain Injury Treatment Receives European Medicines Agency Orphan Medicinal Product Designation
10. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
11. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Pete Rose, baseball,s all-time hits ... and arthritis pain reliever Myoflex, Ducere Pharma has announced. ... we are excited to have him on board with Myoflex," ... "He is a legendary player who is known across all ...
(Date:1/23/2015)... 23, 2015  iMD Companies, Inc. (ICBU) has repositioned itself as ... and grab a foothold in the hydroponic, hemp and medical ... a presence in the sector, and recently partnering with the ... hemp and medical marijuana, iMD is committing to bring its ...
(Date:1/23/2015)... Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), a ... for all forms of sports, including extreme motor sports, ... announced today that the UISP Lega Motociclismo Lombardia, an ... riders to wear a neck brace during its racing ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3
... Where: Laemmle,s Town Center 5, 17200 Ventura Blvd., Encino ... p.m. VIP and remarks following at 4 p.m. Pioneering ... What: Premiere screening of "CODY," the inspiring story of ... Narrated by Glenn Close, the film tells the story of ...
... April 16 Trubion Pharmaceuticals, Inc. (Nasdaq: ... present data regarding its SCORPION(TM) multispecific therapeutic technology ... Association of Cancer Research (AACR) in Denver, April ... present data demonstrating the selectivity and high potency ...
Cached Medicine Technology:University of Redlands Student Cody Unser Documentary Run to Start Today in L.A. 2Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting 2Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting 3
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 EBSCO Information ... (AMA) are expanding their relationship in an effort to further ... the world. While EBSCO has long made AMA journals available ... sales agent for The JAMA Network. , Long ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... macular degeneration (AMD)including an intravitreous (into the eye) injection ... compound approved for use against the eye diseasedo not ... cardiovascular complications or death when compared with existing therapies, ... Archives of Ophthalmology , one of the JAMA/Archives ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, ... your dog home alone without having to worry about chewed ... how to look at the sunny side of life. ... more likely to become distressed and anxious when left alone ...
... , SUNDAY, Oct. 10 (HealthDay News) -- Scientists have found ... for obesity. The findings are reported in two new ... Nature Genetics . , In one report, researchers say they ... the involvement of 14 others. In a second report, the ...
... 2010 A clinical trial at UT Southwestern Medical ... to standard insulin therapy might help rein in the ... diabetes. This is the first type 1 diabetes ... fat cells and involved in body-weight regulation. For this ...
... and structured weight loss programs, can result in significant weight ... two reports that were posted online today by JAMA ... early online to coincide with the presentation of these papers ... The articles will appear in the October 27 print ...
... at UT Southwestern Medical Center have created an experimental ... in the brain and is believed to contribute to ... similar so-called DNA vaccines that the UT Southwestern researchers ... stimulated more than 10 times as many antibodies that ...
Cached Medicine News:Health News:Certain new therapies for age-related eye disease do not appear to increase heart risks 2Health News:Pessimistic Pooches May Be Prone to Separation Anxiety 2Health News:Pessimistic Pooches May Be Prone to Separation Anxiety 3Health News:Researchers Pinpoint Array of Obesity Genes 2Health News:Researchers Pinpoint Array of Obesity Genes 3Health News:UT Southwestern study to determine whether leptin helps type 1 diabetes patients 2Health News:UT Southwestern study to determine whether leptin helps type 1 diabetes patients 3Health News:Clinical trials demonstrate effective weight loss strategies for obese and overweight adults 2Health News:Clinical trials demonstrate effective weight loss strategies for obese and overweight adults 3Health News:UT Southwestern researchers create experimental vaccine against Alzheimer's 2
The Thrombex PMT system is a self-contained, disposable clot-removal device that uses a motor-driven catheter and vacuum source to break up and remove thrombi from a hemodialysis graft....
... AngioJet Xpeedior+120 Rheolytic Thrombectomy catheter is designed ... Powerful saline jets create a low pressure ... vacuum effect. Thrombus is drawn into the ... jets, and removed from the body.,AngioJet thrombectomy ...
... pulse generators are meeting the clinical ... electrophysiologists and anesthesiologists. And, they are ... expect from Medtronic.,Effective pacing with the ... polarity for quick battery changes. ...
... St. Jude Medical offers the world's ... Pacel bipolar pacing catheters are available in ... a broad range of curve choices and ... Pacing Catheter is indicated for use in ...
Medicine Products: